Edoardo Rasciti1, Nicola Sverzellati2, Mario Silva2, Andrea Casadei3, Domenico Attinà3, Massimiliano Palazzini4, Nazzareno Galiè4, Maurizio Zompatori3. 1. Division of Radiology, Department of Surgical Sciences, University of Parma, Parma, Italy. edoardo.rasciti@gmail.com. 2. Division of Radiology, Department of Surgical Sciences, University of Parma, Parma, Italy. 3. Cardiothoracic Radiology Unit, Cardio-Thoracic-Vascular Department, University Hospital S.Orsola-Malpighi, Bologna, Italy. 4. Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.
Abstract
PURPOSE: To test the efficacy of bronchial artery embolization (BAE) to treat haemoptysis in pulmonary hypertension (PH). METHODS: 33 patients were treated by BAE for haemoptysis associated with PH (PH group = 21) or non-associated with PH (control group = 12). The details of procedure, outcome, and rate of relapse were compared between the two groups. Within the PH group, the comparison was operated between subjects with congenital heart disease-associated pulmonary artery hypertension (CHD-APAH subgroup = 12) and non-CHD (non-CHD-APAH subgroup = 9). RESULTS: The rate of relapse at 30 and 90-days was similar between the PH group and control group. BAE in the PH group was more challenging (median 2 arteries embolized per procedure) compared to the control group (median 1 artery embolized per procedure; p = 0.001). Bleeding arteries were more heterogeneous in the PH group, while a single right bronchial artery was the only clinical finding in 66.7% of controls (p = 0.001). Within the PH group, the CHD subgroup showed higher survival rate compared to the non-CHD-APAH group (p = 0.007). CONCLUSION: BAE is effective and safe for the treatment of haemoptysis in PH, yet more challenging than other conditions. In PH-associated haemoptysis, BAE provides higher survival rate for subjects with PH associated with CHD.
PURPOSE: To test the efficacy of bronchial artery embolization (BAE) to treat haemoptysis in pulmonary hypertension (PH). METHODS: 33 patients were treated by BAE for haemoptysis associated with PH (PH group = 21) or non-associated with PH (control group = 12). The details of procedure, outcome, and rate of relapse were compared between the two groups. Within the PH group, the comparison was operated between subjects with congenital heart disease-associated pulmonary artery hypertension (CHD-APAH subgroup = 12) and non-CHD (non-CHD-APAH subgroup = 9). RESULTS: The rate of relapse at 30 and 90-days was similar between the PH group and control group. BAE in the PH group was more challenging (median 2 arteries embolized per procedure) compared to the control group (median 1 artery embolized per procedure; p = 0.001). Bleeding arteries were more heterogeneous in the PH group, while a single right bronchial artery was the only clinical finding in 66.7% of controls (p = 0.001). Within the PH group, the CHD subgroup showed higher survival rate compared to the non-CHD-APAH group (p = 0.007). CONCLUSION:BAE is effective and safe for the treatment of haemoptysis in PH, yet more challenging than other conditions. In PH-associated haemoptysis, BAE provides higher survival rate for subjects with PH associated with CHD.
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Herre J Reesink; Otto M van Delden; Jaap J Kloek; Henk M Jansen; Jim A Reekers; Paul Bresser Journal: Cardiovasc Intervent Radiol Date: 2007 Jan-Feb Impact factor: 2.740
Authors: A Poyanli; B Acunas; I Rozanes; K Guven; S Yilmaz; A Salmaslioglu; E Terzibasioglu; R Cirpin Journal: Br J Radiol Date: 2007-03-28 Impact factor: 3.039
Authors: A S Jensen; P I Johansson; L Idorn; K E Sørensen; U Thilén; E Nagy; E Furenäs; L Søndergaard Journal: Int J Cardiol Date: 2012-05-10 Impact factor: 4.164